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Abstract
In patients treated with macitentan (Opsumit, Actelion Pharmaceuticals Ltd., Basel, Switzerland) for pulmonary arterial hyper-
tension (PAH), prevention and/or effective management of treatment-related adverse events may improve adherence. However,
management of these adverse events can be challenging and the base of evidence and clinical experience for macitentan is limited.
In the absence of evidence, consensus recommendations from physicians experienced in using macitentan to treat PAH may benefit
patients and physicians who are using macitentan. Consensus recommendations were developed by a panel of physicians experi-
enced with macitentan and PAH using a modified Delphi process. Over three iterations, panelists developed and refined a series of
statements on the use of macitentan in PAH and rated their agreement with each statement on a Likert scale. The panel of
18 physicians participated and developed a total of 118 statements on special populations, add-on therapy, drug–drug interactions,
warnings and precautions, hospitalization and functional class, and adverse event management. The resulting consensus recom-
mendations are intended to provide practical guidance on real-world issues in using macitentan to treat patients with PAH.
Keywords
endothelin receptor antagonist, adverse events, therapy adherence
Date received: 17 February 2017; accepted: 24 June 2017
Pulmonary Circulation 2017; 7(3) 702–711
DOI: 10.1177/2045893217721695
Macitentan (Opsumit, Actelion Pharmaceuticals Ltd.,
Basel, Switzerland) is a dual endothelin receptor antagonist
(ERA) that was approved in the United States in 2013 for
the treatment of pulmonary arterial hypertension (PAH)
(World Health Organization [WHO] Group 1) based on
data from the pivotal SERAPHIN trial.1,2 Macitentan,
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like other ERAs, can cause a spectrum of adverse effects
ranging from minor nuisance problems to severe adverse
drug reactions, some of which may be difficult to differenti-
ate from disease-related complications. When using targeted
therapies such as macitentan to manage patients with PAH,
prevention and/or effective management of these adverse
events may help optimize adherence and set expectations
to keep patients on treatment.3
Nonetheless, optimizing the prevention and management
of adverse events can be challenging and the best strategies
have not been defined. The challenge may be particularly
acute for recently introduced medications, such as maciten-
tan, due to a limited base of evidence and clinical experience
on adverse event management. The prescribing information
and published pivotal trial data on macitentan provide an
essential foundation of knowledge on its efficacy, safety, and
use. However, these sources do not incorporate important
real-world, experiential learning on the practical use of
macitentan, such as detailed data on adverse event manage-
ment and dose titration reports.
Physicians who use macitentan in treating patients with
PAH need to alleviate or prevent macitentan-related adverse
events and manage other specific circumstances appropri-
ately, despite the paucity of relevant evidence and lack of
evidence-based recommendations. Both physicians and
patients may benefit from expert advice from physicians
experienced in the treatment of PAH and the use of maci-
tentan.4 The Delphi method is a well-known approach for
developing and recording consensus advice when evidence is
not available.5–10 The study is intended to provide consensus
recommendations for the management of PAH with maci-
tentan based on the current practice in the United States
using a Delphi process with a panel consisting of US-
based physicians familiar with this medication.
Methods
A modified Delphi process was used to develop the consen-
sus. The Delphi process was originally described by Delbecq
et al. and has been reviewed previously.11–15 The current
study was conceived by one author (FFR), who also
served as a study moderator and recruited the Delphi pan-
elists. The target Delphi panel size was 20 members.
Initially, the US investigators in the SERAPHIN pivotal
trial of macitentan with the largest numbers of patients
were invited to participate. Then, members of the
Pulmonary Hypertension Association who were located in
the United States and listed in the Association’s database as
managing at least 200 patients with pulmonary hypertension
were then invited in alphabetical order until the target panel
size was reached. The 200-patient threshold was selected
because it represents the most experienced category listed
in the Pulmonary Hypertension Association database and
because the moderators felt that it was adequate to demon-
strate appropriate expertise in PAH for the purposes of the
study. The actual number of patients with PAH under active
management was verified by panelist self-report. All panel-
ists who participated actively in the Delphi process (defined
as completing and returning at least two out of three ques-
tionnaires including the final questionnaire, and reviewing
the draft and final manuscripts) met the International
Committee of Medical Journal Editors criteria for author-
ship and are included as co-authors.
For this study, the modified Delphi procedure used three
questionnaires, which included statements based on the
macitentan prescribing information,1 the published results
of the SERAPHIN trial,2 and the panelists’ clinical experi-
ence. The procedure was as follows (Fig. 1):
1. The moderator (FFR) developed an initial questionnaire
based on available clinical trial evidence and the maciten-
tan package insert.1,2,16,17 The initial questionnaire was a
topically organized spreadsheet with multiple statements
relevant to the use of macitentan. Panelists were requested
to provide open-ended comments on each statement and
to add additional relevant statements at their discretion.
The initial questionnaire was circulated to the Delphi pan-
elists by email. Panelists responded independently.
2. At this point two moderators (FFR and HIP) reviewed
and summarized responses to the initial questionnaire
and used the responses to develop a second questionnaire
spreadsheet that incorporated the initial statements and
additional statements added by the panelists without
changing the overall organization. The second question-
naire requested panelists to rate each statement on a
numeric Likert scale ranging from –3 (strongly disagree)
to 3 (strongly agree). The second questionnaire was cir-
culated to the Delphi panelists by email.
Develop initial
questionnaire (FFR)
6 topics
Review and summarize responses (FFR and HIP)
Develop a revised questionnaire
Circulate and review final results (All authors)
Recruit 18 panelists
 8 from the
SERAPHIN trial
10 not from the
SERAPHIN trial
Questionnaire 1 
Based on clinical trial evidence and the macitentan 
package insert
Circulate to panelists and collect responses
Questionnaire 2
added by panelists; Likert scale ranging from -3 to +3
Circulate to panelists and collect responses
Final questionnaire
Incorporates responses to questionnaire 2;
118 statements; Likert scale from -5 to +5 
Circulate to panelists and collect responses 
Includes statements from questionnaire 1 and statements  
Review and aggregate responses (FFR and HIP) 
Fig. 1. The Delphi process used in the study.
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3. The moderators reviewed and aggregated responses to
the second questionnaire into a summary spreadsheet
and used them to refine the questionnaire to create a
third and final version, shown in Figs. 3–8. The final
questionnaire requested panelists to rate each statement
on a numeric Likert scale ranging from –5 (strongly dis-
agree) to 5 (strongly agree) to improve discriminant abil-
ity. In addition, several questions asked panelists to select
a time period rather than indicate their agreement/dis-
agreement. Details of the time periods are shown in
Figs. 1 and 4. The summary and the final questionnaire
were circulated to the Delphi panelists by email.
4. The results of the final questionnaire were aggregated
into a summary spreadsheet and circulated to the panel-
ists for review and comment.
Following standard practice for the Delphi methodology,
the panelists’ anonymity was maintained throughout the
process. Anonymity is deemed essential in Delphi method-
ology to prevent bias by influential clinicians and to reduce
the pressure towards conformity. Panelists were encouraged
to comment on the validity, specificity, and content of the
items under consideration. All comments were incorporated
verbatim and anonymously in the statements and question-
naires distributed to panelists in each round. Panelists were
also encouraged to provide questionnaires and provide rele-
vant literature. All literature referenced in the statements
was circulated to the entire panel for reference and inde-
pendent examination.
Consensus was defined prospectively as a mean panelist
rating 2.5 or  –2.5 on the –5 to þ5 Likert scale used in the
final questionnaire, with a standard deviation that did not
cross zero (Fig. 2). Strong, moderate, and weak recommen-
dations were defined retrospectively as a mean panelist
rating absolute value 4.0 (strong recommendation), 3.0
and<4.0 (moderate recommendation), and 2.5 and <3.0
(weak recommendation). Consensus was not defined for
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if average <2.5 and >-2.5 or SD crosses 0; not recommended if average <-2.5 and SD crosses 0. 
Consensus was not defined for questions answered with a time period rather than the Likert scale.
How do you treat 
patients who are
temporarily unable 
to take macitentan
orally? 
How do you treat 
patients who must 
forgo taking
macitentan for an
extended period? 
NA: not available
A patient can safely forgo treatment with macitentan 
for ______ 
Macitentan can be crushed and administered 
though NG/feeding tube for intubated patients 
Restart patient on macitentan schedule if ______ days 
of doses missed 
Switch to another therapy if ______ days are missed
Assess health (e.g., labs and/or exam) of patient
Alter PAH therapy regimen (e.g., increase dosage of 
PDE5-i above baseline), if indicated
Counsel patients on importance of compliance
NA NA
0.7 3.6
NA
NA
NA
NA
4.1 1.2
2.2 2.5
4.9 0.3
Fig. 3. Delphi consensus results—special patient populations. Recommendations that achieved consensus are in bold.
Neither agree
nor disagree
Strongly
disagree
Strongly
agree
0-1 1 2 3 4 5-2-3
Consensus
-4-5
Moderate Consensus
Strong Consensus
Consensus
Moderate Consensus
Strong Consensus
Fig. 2. The Likert scale used in the final stage of the Delphi process.
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questions answered with a time period rather than the
Likert scale.
Results
A total of 18 physicians joined the Delphi panel,
including eight SERAPHIN investigators and ten members
of the Pulmonary Hypertension Association who were not
SERAPHIN investigators. The number of patients with
PAH under active management for individual panelists
was in the range of 90–1200. All 18 panelists participated
actively in the Delphi process. The final Delphi question-
naire was divided into six topics including 118 statements.
All statements and the results of the final questionnaire are
shown in Figs. 3–8.
Panelists strongly recommended that patients who have
forgone macitentan for an extended period should undergo
a health assessment and be counseled on the importance of
compliance (Fig. 3). Consensus was not evaluated on the
duration for which patients can safely forgo treatment
with macitentan, when macitentan should be restarted
after missing doses, or when another therapy should be
started after missing macitentan doses.
Panelists reached a consensus that macitentan can be
used as dual therapy with oral phosphodiesterase type 5
inhibitors (PDE5-i) and oral, inhaled, or intravenous (IV)
prostanoids. The strongest recommendation was for use
with PDE5-i (Fig. 4). Panelists also reached consensus that
macitentan has clinically relevant drug–drug interactions
with ketoconazole and rifampin and should not be used
concomitantly with these agents (Fig. 5).
The group recommended laboratory testing when initiat-
ing macitentan, with a strong consensus for laboratory test-
ing generally and the following specific tests: complete blood
count; liver function tests; pregnancy test (in women of
childbearing potential); and brain natriuretic peptide or N-
terminal pro b-type natriuretic peptide (NT-proBNP). There
was a weak consensus for also ordering a complete meta-
bolic panel. Most panelists recommend monthly pregnancy
testing with a complete blood count, liver function testing, a
comprehensive metabolic panel, and brain natriuretic pep-
tide assessments every three months (Fig. 6). Note that the
-7.5 -5 -2.5 0 2.5 5 7.5
Mean Delphi Score
Topic Statement Mean StdDev
if average <2.5 and >-2.5 or SD crosses 0; not recommended if average <-2.5 and SD crosses 0.
*The prescribing information for macitentan includes information relevant to this statement.
Macitentan + Oral PDE-5 inhibitors*1
Macitentan + Oral prostanoids
Macitentan + Inhaled prostanoids*1
Macitentan + IV prostanoids
Macitentan + Calcium channel blockers 
Use as a dual PAH therapy
Use as a component of triple therapy
Use as a dual PAH therapy
Use as a component of triple therapy 
Use as a dual PAH therapy
Use as a component of triple therapy
Use as a dual PAH therapy
Use as a component of triple therapy 
Use as a dual PAH therapy
Use as a component of triple therapy
4.3 1.1
3.9 1.3
3.3 2.1
3.4 2.0
3.4 2.0
3.3 1.9
3.4 1.7
3.8 1.4
-0.1 3.3
0.3 3.4
Fig. 4. Delphi consensus results—use of add-on therapy, ‘‘What is your opinion of co-administering macitentan with other PAH therapies?’’
Recommendations that achieved consensus are in bold.
-7.5 -5 -2.5 0 2.5 5 7.5
Mean Delphi Score
Topic Statement Mean StdDev
if average <2.5 and >-2.5 or SD crosses 0; not recommended if average <-2.5 and SD crosses 0.
*The prescribing information for macitentan includes information relevant to this statement.
Macitentan + Cyclosporine A
Macitentan + Ketoconazole*1
Macitentan + Rifampin*1
Macitentan + Sildenafil*1
Macitentan + Warfarin*1
Clinically relevant drug-drug interaction:
avoid use together
Clinically relevant drug-drug interaction:
avoid use together
Clinically relevant drug-drug interaction:
avoid use together
There is no clinically relevant drug-drug interaction
There is no clinically relevant drug-drug interaction
1.7 3.8
3.8 1.9
3.7 1.9
2.7 3.4
2.9 3.4
Fig. 5. Delphi consensus results—drug–drug interactions. Recommendations that achieved consensus are in bold.
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prescribing information for macitentan requires monthly
pregnancy testing for all women of childbearing potential
taking macitentan.
The panelists recommended that prior hospitalization for
PAH should not affect use of macitentan. In addition, pan-
elists strongly recommended use of macitentan as part of a
combination in treating patients with modified New York
Heart Association functional class (FC) II, III, or IV and as
single agent therapy for FC II (Fig. 7). Use of macitentan as
a single agent is not recommended for patients with FC IV.
There was also a consensus for use of macitentan in patients
with mild renal impairment or if hemodynamically stable.
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if average <2.5 and >-2.5 or SD crosses 0; not recommended if average <-2.5 and SD crosses 0. 
Consensus was not defined for questions answered with a time period rather than the Likert scale.
*The prescribing information for macitentan includes information relevant to this statement.
What laboratory tests 
would you order prior to 
initiating macitentan?  
How frequently would 
you order the following 
tests following initiation 
of macitentan? 
Order laboratory test(s) when initiating 
macitentan therapy*1 
Order complete blood count (CBC)*1
Order liver function tests (LFT)*1
Order comprehensive metabolic panel (CMP) 
Order pregnancy test*1
Order Brain Natriuretic Peptide (BNP)/
NT-ProBNP
4.5 1.7
4.6 1.2
4.8 0.7
3.1 2.8
4.9 0.2
1.54.2
Complete blood count (CBC)*1 
Liver function tests (LFT)*1 
Comprehensive metabolic panel (CMP) 
Pregnancy test*1 
Brain Natriuretic Peptide (BNP)/NT-ProBNP
2.8 1.5
3.2 1.6
4.1 2.8
2.0 1.8
4.2 1.5
Fig. 6. Delphi consensus results—warnings and precautions. Recommendations that achieved consensus are in bold.
-7.5 -5 -2.5 0 2.5 5 7.5
Mean Delphi Score
Topic Statement Mean StdDev
Prior all-cause hospitalization does not affect
prescription of macitentan 
Hospitalization
2.5 2.9
2.9 2.4Prior PAH-related hospitalization does not affectprescription of macitentan 
How does the
Functional Class of 
a patient affect your 
decision to prescribe 
macitentan?*1  
How does a patient’s 
organ or tissue 
function affect your 
decision to prescribe 
macitentan?*1  
FC I (single agent)
FC I (combination)
FC II (single agent)
FC II (combination)
FC III (single agent)
FC III (combination) 
FC IV (single agent)
FC IV (combination)
Prescribe if possible diastolic dysfunction
Prescribe if mild renal impairment
Prescribe if edema
Prescribe if hemodynamically stable
Prescribe if hemodynamically unstable after 
prostacyclin initiation 
-0.1 3.6
-1.9 2.6
3.1 2.1
3.6 1.8
0.4 2.8
4.3 1.4
-4.1 2.2
2.9 2.0
0.8 3.1
3.3 2.0
2.4 2.0
3.7 1.8
1.4 2.7
if average <2.5 and >-2.5 or SD crosses 0; not recommended if average <-2.5 and SD crosses 0.
*The prescribing information for macitentan includes information relevant to this statement.
Fig. 7. Delphi consensus results—hospitalization. Recommendations that achieved consensus are in bold.
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Fig. 8. Delphi consensus results—adverse events frequency and management.
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The panelists provided several consensus recommenda-
tions for management of common adverse events. See
Fig. 8 for the strength of these recommendations.
Upper respiratory tract infections
No consensus recommendations.
Peripheral edema
A patient who develops edema should be educated on diet
and advised to restrict fluid and sodium intake. Loop-inhi-
biting diuretics, spironolactone, compression stockings,
and/or elevation are also recommended. Macitentan
should be discontinued if severe, persistent edema continues
despite these measures.
Nasopharyngitis and pharyngitis
Nasopharyngitis and pharyngitis can be treated symptom-
atically, including nasal corticosteroids or other nasal
sprays, saline rinses, and nasal irrigation.
Right ventricular failure
Management for right ventricular failure should include
right heart catheterization (RHC), inotropic agents if
needed, and maximization of PAH medications, advancing
to dual or triple PAH therapy if possible. In addition, diur-
etics should be maximized (including IV diuretics) and fluid
status controlled. There was no consensus on whether maci-
tentan should be stopped in patients with right ventricular
failure.
Headache
Headache can be minimized by administering macitentan at
bedtime and not concurrently with PDE5-i. Acetaminophen
and symptomatic care are acceptable to manage patient
discomfort.
Anemia
Patients with anemia should be monitored, should
receive iron replacement as needed, and should avoid
volume overload. No change in macitentan therapy is
needed for mild anemia, but severe and/or persistent
anemia without identifiable cause may require discontinu-
ation of macitentan.
Dizziness
Patients who develop dizziness should be evaluated for the
status of their PAH and for postural hypotension, and may
need adjustment or discontinuation of diuretics (fluid man-
agement) and/or antihypertensive medications.
Bronchitis
Use of a metered-dose inhaler and pneumonia and influenza
vaccinations are recommended for patients who develop
bronchitis.
Dyspnea
Patients who develop dyspnea should receive an echocardio-
gram and should be evaluated for fluid status and lung dis-
ease, including an assessment of whether the dyspnea is
related to PAH. These patients should restrict their
sodium intake and may need to alter the use of diuretics
and/or their PAH-directed therapy. RHC is warranted if a
patient’s PAH status has changed.
Cough
Benzonatate capsules are suggested for managing cough,
though other antitussives can be considered.
Infectious disease (influenza and urinary tract infection)
Common infections may be managed with symptomatic care
and appropriate anti-infective agents, e.g. oseltamivir or
other antivirals for influenza and antibiotics for urinary
tract infections. Patients should receive influenza vaccinations
annually. For patients who develop influenza, symptomatic
care with Tamiflu and/or antivirals are recommended.
Immune/Allergic disorders
If immune system disorders develop (e.g. allergic reaction or
angioedema, pruritus, or rash), it is important to establish
the etiology. Patients with rash or pruritus should be
referred to a dermatologist. If appropriate, macitentan
should be discontinued and/or therapy with antihistamines
and steroids initiated.
General disorders and administration
(edema/fluid retention)
It is critical to educate the patient on dietary, fluid, and
sodium restrictions and to assess adherence to these recom-
mendations. In addition, a diuretic should be initiated or, if
the patient is already on a diuretic, the diuretic regimen
should be adjusted as needed. Spironolactone should be
added routinely and volume should be managed using a
weight-based strategy like that used with congestive heart
failure (CHF). If edema or fluid retention is severe and per-
sistent, consider discontinuing macitentan.
Discussion
This report is intended to assist physicians who use maci-
tentan in managing patients with PAH by providing expert
guidance for aspects of care relating to treatment-related
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adverse events and interruptions in therapy for which little
or no real-world evidence-based data are available. The con-
sensus recommendations presented here were developed by
a panel of physicians experienced with macitentan and PAH
using a modified Delphi methodology. The Delphi process
developed a total of 118 statements and the panel reached
consensus on 89 of those statements.
The panelists reached a strong consensus on several recom-
mendations. Macitentan is appropriate as a part of dual or
combination therapy with PDE5-i or prostanoids for patients
in FC II–IV. Short interruptions in macitentan therapy can
usually be tolerated, but longer interruptions should be man-
aged by restarting macitentan or some other PAH therapy.
Panelists made several strong consensus recommenda-
tions related to adverse event management. Notably, panel-
ists unanimously and strongly agreed on the importance of
educating and counseling patients on diet, fluid, and sodium
restrictions and the importance of adherence. Appropriate,
effective education and counseling can often help control
fluid status and thereby prevent or alleviate common
events such as edema and dyspnea. Optimization of the
patient’s diuretic regimen to control fluid status is also crit-
ical for managing these adverse events. In patients who
develop right ventricular failure, medications directed at
PAH should be maximized, possibly by adding or increasing
a prostanoid, in addition to other measures aimed at con-
trolling fluid status (optimization of diuretics). These
patients should also be evaluated by echocardiogram.
Other strong recommendations focused on anemia and
infectious disease. Patients should be monitored for
anemia and treated as appropriate to help keep them on
therapy. However, macitentan should be discontinued if
anemia is severe and/or persistent and without identifiable,
treatable etiology. All patients should receive pneumonia
and influenza vaccinations.
The Delphi method is a broadly accepted strategy for
developing consensus recommendations based on expert
opinion. A key strength of the Delphi method is its use of
a systematic, anonymous process that promotes free sharing
of opinions and ideas, weights all panelists’ opinions
equally, and makes it difficult for any individual panelist
to dominate the process.
For this study, the Delphi method was implemented using
electronic communications to collect and disseminate infor-
mation. A clear advantage of this approach is that use of
electronic communications minimizes any need for travel or
fixed time commitments; therefore, it facilitates panelists’ par-
ticipation in the process at low cost while respecting their
other important time commitments. Use of electronic com-
munications also helps maintain the anonymous nature of the
Delphi process.
Limitations
The Delphi process has several limitations. There is cur-
rently no generally accepted criterion defining consensus in
Delphi studies, and given the wide variety of topics investi-
gated using the Delphi approach, it may not be possible to
define generally applicable criteria.6,7,18 As expected for a
process intended to provide guidance when no strong evi-
dence is available, the process is not scientifically or statis-
tically rigorous, and even if consensus is reached, there is no
guarantee that the consensus answer is correct.7,9,18
Panel selection and the development of the initial ques-
tionnaire may have inadvertently introduced bias into the
process.6,13 In this study, the selection of expert panelists
was limited to 20 US-based participants to help ensure
that the Delphi process was manageable. Although the
panel as a whole has broad and deep experience with
PAH and with macitentan, panelists outside of the US
were not included. As a result, the Delphi consensus may
not represent perspectives from outside the US. In addition,
it may have missed important perspectives from a larger
population of US-based physicians due to the small
sample size. Other potential stakeholders, such as patients,
pharmacists, and payers, were also not included.
Although anonymity is an important aspect of the Delphi
process, it means that panelists are not accountable for their
responses, possibly leading to responses based on insuffi-
cient or minimal consideration.18 The panelists had a wide
range of experience within 200þPAH patient criterion.
Panelists less experienced in the disease area in question
may have a voice disproportionate to their knowledge of
the disease, so that less experienced panelists can vote
against and effectively discount tried-and-tested strategies
proposed by more experienced panelists. This issue is unli-
kely to have been significant in this study because the pan-
elists were selected for their experience with macitentan and
PAH, and inclusion of panelists with differing levels of
expertise related to the study will have helped ensure the
manuscript captures the full range of opinions.13
In conclusion, we used the Delphi process to develop
expert consensus recommendations on the use of macitentan
in managing patients with PAH. The recommendations are
intended to provide practical guidance on clinical questions
related to but not fully covered in the package insert and
pivotal trial reports for macitentan.
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